Relieves osteoarthritis and rheumatoid arthritis. ANDA 203166, held by Lgm Pharma. Nabumetone.
As of Nov 15, 2026, ANDA 203166 (Nabumetone), held by Lgm Pharma, was first approved by FDA on Aug 30, 2019, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Carefully consider the potential benefits and risks of nabumetone tablets and other treatment options before deciding to use nabumetone tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. Nabumetone tablets are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 30, 2019 | Original application | Approved |
| Nabumetone500MG · tablet;oral | Nabumetone | Rx |
| Nabumetone750MG · tablet;oral | Nabumetone | Rx |
| Nabumetone1GM · tablet;oral | Nabumetone | Rx |
| Nov 22, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 28, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 30, 2019 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters